Selling, General, and Administrative Costs: Genmab A/S vs Celldex Therapeutics, Inc.

SG&A Expenses: Genmab A/S vs. Celldex Therapeutics, Inc. (2014-2023)

__timestampCelldex Therapeutics, Inc.Genmab A/S
Wednesday, January 1, 20142062200079529000
Thursday, January 1, 20153383700091224000
Friday, January 1, 201635979000102413000
Sunday, January 1, 201725003000146987000
Monday, January 1, 201819269000213695000
Tuesday, January 1, 201915426000342000000
Wednesday, January 1, 202014456000661000000
Friday, January 1, 2021204880001283000000
Saturday, January 1, 2022271950002676000000
Sunday, January 1, 2023309140003297000000
Monday, January 1, 20243790000000
Loading chart...

Unlocking the unknown

A Comparative Analysis of SG&A Expenses: Genmab A/S vs. Celldex Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Genmab A/S has consistently outpaced Celldex in SG&A spending, reflecting its expansive operational scale. In 2023, Genmab's SG&A expenses surged to approximately 3.3 billion, marking a staggering 314% increase from 2014. In contrast, Celldex's expenses grew by about 50% over the same period, reaching around 31 million. This disparity highlights Genmab's aggressive market strategies and broader operational footprint. As the industry continues to grow, monitoring these financial trends offers valuable insights into the strategic priorities and market positioning of these biotech giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025